Assess whether a CMO finding is a delay or a refuse-to-file risk (bc08ff)

Situation

An RWE group proposing a post-marketing study instead of a new RCT cannot treat a site-change that invalidates stability claims as color commentary on RWE protocol that may not meet regulator expectations. RWE evidence-strategy director must close a CMO finding is from that extract under Pharma & Life Sciences / Pharmacovigilance.

Decision

RWE evidence-strategy director in an RWE group proposing a post-marketing study instead of a new RCT must choose A CMO finding is a delay / A refuse-to-file risk using RWE protocol that may not meet regulator expectations after a site-change that invalidates stability claims.

Hypotheses to test

• A site-change that invalidates stability claims is noise around an already-controlled Pharmacovigilance process in an RWE group proposing a post-marketing study instead of a new RCT, given RWE protocol that may not meet regulator expectations.
• A site-change that invalidates stability claims is the event in RWE protocol that may not meet regulator expectations that forces A CMO finding is a delay for RWE evidence-strategy director under Pharma & Life Sciences.
• RWE protocol that may not meet regulator expectations shows a one-file miss after a site-change that invalidates stability claims, not a Pharmacovigilance program failure.
• RWE protocol that may not meet regulator expectations cannot decide a CMO finding is yet after a site-change that invalidates stability claims; hold is the only Pharma & Life Sciences close an RWE group proposing a post-marketing study instead of a new RCT can defend.

Analysis required

• Check whether RWE protocol that may not meet regulator expectations supports the labeled claim RWE evidence-strategy director would keep.
• Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT.
• Trace CMC, labeling, or pharmacovigilance facts in RWE protocol that may not meet regulator expectations after a site-change that invalidates stability claims.
• For this Pharma & Life Sciences Pharmacovigilance file, read RWE protocol that may not meet regulator expectations against a site-change that invalidates stability claims and write the one fact that would move a CMO finding is for RWE evidence-strategy director.

Recommendation